📅 May 15, 2025
Ticker: $105.09, -0.51% (as of May 14, 2025, 4:00 PM ET)
🧪 Funanc1al Biotech Briefing with a Twist
For more resources on Ligand Pharma's financial statements,
Check this out.

🔔 Nasdaq Bell? More Like Bull Bell

Ligand Pharma is set to ring the opening bell on May 19. But what exactly are we celebrating? A new blockbuster drug? A royalty jackpot? Or a $1M insider bet?

🎯 Insider Trigger: Double Buy Blitz!

💼 CEO Todd Davis bought 9,510 shares @ $105.20 → +6% stake → $1,000,456
💰 CFO Octavio Espinoza picked up 1,500 shares @ $104.06 → +6% stake → $156,090

That’s not nibbling. That’s a biotech buffet. 🍽️🧬

🧬 What Is Ligand Pharma?

Ligand isn’t your typical lab coat startup. It’s a royalty-based biotech juggernaut.

It doesn’t just develop drugs—it co-owns the income streams from dozens of therapies across nearly every therapeutic category:

💉 Oncology, Neurology, Respiratory
🧠 CNS, Ophthalmology, Cardiology
🦠 Infectious disease, Rare disease
💥 Even Cannabinoid Intoxication (yeah, that’s a thing)

If there's a molecule for it, Ligand’s probably collecting royalties on it.

Interested in investing in a leading-edge biotech?
How about Crispr Therapeutics (CRSP)?
Go ahead, check this out.

📈 Q1 2025: Royalty Check Incoming

Revenue: $45.3M (+46% YoY)
Royalties: $27.5M (+44%)
Captisol sales: $13.5M (+47%)
Adjusted EPS: $1.33 (up from $1.20)
GAAP EPS: 😬 -$2.21 loss (ouch)

🧾 Key driver of that red ink? A $44M one-time R&D funding charge for a new royalty-backed clinical deal.

💬 CEO Quote of the Quarter:

“Our royalty aggregation model stands out in a tough biopharma market. And now with ZELSUVMI backed by strategic investors, we’re dialing up the value creation.” 🎙️💸

📚 Institutions Are in the League, Too

Institutional Ownership: 101.48% of float
Major Players:

• BlackRock (15.14%)

• Vanguard (10.65%)

• Janus Henderson, Macquarie, State Street…
  Wall Street’s not just watching. They’re holding—and hard. 🏦📊

🔍 For full Institutional Ownership breakdown, see here

⚖️ Valuation Snapshot

• 2024 P/E: –477.68 (we don’t talk about that one)

• 2025 Forward P/E: 37.27

• 2026 Estimates: 25.38

• 2027 Estimates: 22.85

Yes, it’s pricey—until you factor in scale, margins, and its plug-and-play revenue model. This isn’t a one-hit wonder. It’s the Spotify of pharma royalties.

🧠 What’s the Bull Case?

✅ Expanding royalty streams 💰
✅ Solid management (skin in the game!)
✅ 46% revenue growth? Not a typo 🔥
✅ Low debt-to-equity (0.86%)
✅ Strong institutional backing 🧱
✅ Healthy cash pile ($208.9M) + Viking stake kicker 🧊🐉

Translation: It’s weird, it’s niche, it’s diversified—and it works.

🧨 What Could Go Wrong?

❌ Clinical failures (happens in biotech)
❌ Wall Street biotech apathy
❌ Sector-wide meltdown
❌ Existential crises… or Mars Attacks 👽

But Ligand isn’t chasing moonshots—it’s licensing, collecting, reinvesting, and playing biotech chess while others are still learning molecules. 🧬♟️

📌 Verdict: A League of Its (Almost) Own

Ligand is not trying to cure everything. It’s just trying to earn a piece of everything. And with insider buys, loyal funds, and a royalty model that prints cash (when it’s not funding Viking stock), there’s a compelling contrarian play here.

🏆 If biotech’s a casino, Ligand owns the table.

📉 Disclaimer: We’re not your financial advisors. We’re barely your comedy advisors. Consult a real pro before investing. Preferably one who understands molecules and metaphors.

🧭 Want More Like This?

Check out our Insider Purchases Hub
Or browse our Turnaround Plays Section